Arena moves PAH drug forward despite Phase Ib adverse event
This article was originally published in Scrip
Executive Summary
Arena Pharmaceuticals is moving ahead with a Phase II clinical trial for its pulmonary arterial hypertension (PAH) drug APD811 based on data from two Phase I trials, including an incidence of transient atrial fibrillation that may have been caused by the company's oral prostacyclin (IP) receptor agonist.
You may also be interested in...
Arena Rises, But Raises Questions With Phase II Ralinepag Data In PAH
Arena reported statistically and "clinically" significant results from its Phase II study for ralinepag in pulmonary arterial hypertension (PAH), driving its share price up by more than 40%, but details expected later this year or in 2018 are needed to shed more light on the data.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.